1. Introduction
===============

Chronic periodontitis (CP) is a common inflammatory disease which involves the supporting tissue of teeth, and gradually destroys alveolar bone and connective tissue ([@b1-epj-09-4961], [@b2-epj-09-4961]). It is widely accepted that the destruction of periodontal tissue is a result of host immune inflammatory response caused by periodontal microorganisms ([@b3-epj-09-4961], [@b4-epj-09-4961]). The white blood cells (WBCs) and macrophages are triggered to produce inflammatory mediators, including cytokines, chemokines and proteolytic enzymes, which may cause tissue degradation and bone resorption ([@b5-epj-09-4961], [@b6-epj-09-4961]). A major risk factor for the development and progression of CP is cigarette smoking ([@b7-epj-09-4961]--[@b11-epj-09-4961]). The destructive effect of smoking has been attributed to an alteration in the microbial flora and host immune inflammatory response ([@b12-epj-09-4961], [@b13-epj-09-4961]). Nicotine in cigarettes provokes inflammation and causes vasoconstriction and scar formation ([@b14-epj-09-4961]). Other cytotoxic substances included in cigarettes have an important role in cell migration and secretion of inflammatory mediators ([@b15-epj-09-4961], [@b16-epj-09-4961]). The direct effect of smoking on periodontal tissue includes gingival fibrosis, decreased bleeding on probing (BOP) and decreased gingival crevicular fluid (GCF) ([@b17-epj-09-4961]). In general, it has been shown that the clinical signs of inflammation and BOP are less evident in smokers compared with non-smokers ([@b18-epj-09-4961], [@b19-epj-09-4961]). Souto et al. ([@b20-epj-09-4961]) reported that smoking decreased both inflammatory infiltrate and dendritic cells in samples of chronic gingivitis. Smoking also has a deleterious effect on the outcome of periodontal treatments ([@b12-epj-09-4961], [@b21-epj-09-4961], [@b22-epj-09-4961]). Examinations on blood samples and gingival crevicular fluid of subjects with chronic periodontitis showed that smoking increased production of cytokines ([@b23-epj-09-4961], [@b24-epj-09-4961]). Fatemi et al. ([@b25-epj-09-4961]) reported that toll like receptors (TLR) 2 and 4 expression were higher among smoker subjects. Low levels of clinical inflammation among smokers on one hand and increase in bone resorption and tissue degradation on the other, may seem paradoxical and the proportion of chronic inflammatory cell infiltrates needs to be better understood. Therefore, the aim of this study was to examine the chronic inflammatory cell infiltrates in gingival tissue of affected periodontitis and healthy periodontal gingiva of smoker and non-smoker subjects using immunohistochemistry (IHC).

2. Material and Methods
=======================

2.1. Research design and participants
-------------------------------------

The study population was selected from a pool of referrals to the Department of Periodontology of Mashhad Dental School in 2016. Since similar studies have not been done, we performed this study as a pilot. The power of study indicated that the sample size was sufficient (study power: 90%). The study groups consisted of 20 smoker, and 21 non-smoker patients. These patients required periodontal surgery because of their periodontal disease. Only heavy smokers (case) and never smokers (control) were included in the sample in order to minimize the masking effect of inclusion of occasional smoker patients. Heavy smoking was defined as smoking twenty or more cigarettes per day as reported by the patients themselves. The patients who had systemic disease or used antibiotics within the past month were excluded from the study. No biochemical analysis was conducted to verify and quantify the smoking status of patients. All patients had periodontitis affected sites. Therefore, an initial phase of periodontal treatment including oral hygiene instruction and non-surgical mechanical debridement was carried out for all patients. Six weeks following the initial phase, sites still showing pocket depth (PD \>5 mm) and BOP+ were allocated to surgical pocket elimination. Each patient provided two biopsy samples which were harvested during his surgery. One sample was from periodontally diseased sites PPD\>5 and BOP+. The other biopsy was taken from adjacent healthy sites. Therefore, the study consisted of 4 groups. In groups one and three the patients were smokers who smoked one or more pack of cigarettes. Mild smokers were deliberately excluded in order to prevent masking of any possible differences with non-smokers. Group two and four consisted of non-smoker subjects. In groups 1 and 2, biopsy samples were taken from periodontally healthy sites whereas in groups 3 and 4, the sampled sites periodontal pockets depth \>5mm and BOP. The age range of patients were between 35 and 65 years. Patients on medication known to interfere with periodontal pathology such as antibiotics or anti-inflammatory drugs were excluded. Furthermore, aggressive periodontitis patients were not included in the study. All patients signed a written consent form prior to inclusion into the study. The biopsies were taken 3 to 5 mm from the papilla tip ensuring that it included oral epithelium and sulcular epithelium, junctional epithelium and connective tissue. A horizontal mucoperiosteal incision at right angle to the buccal interproximal bone was done, separating the papilla tip from the rest of gingival. An interdental knife (Goldmanfox, HU-Friedy Mfg Co, Chicago, IL) was used to separate the excised gingival.

2.2. Immunohistochemistry
-------------------------

For IHC, four slices with a thickness of 4 μm were prepared from each paraffin-embedded section. The sections were fixed on poly-L-Lysine-coated glass slides. Deparaffinized and rehydrated slides were incubated for 30 minutes in 3% hydrogen peroxide/methanol to stop endogenous peroxidase activity, and then irrigated with phosphate-buffered saline (PBS) for 20 minutes. For antigen retrieval, the sections were microwaved in citrate solution (0.01 M, pH 6.0) for 35 minutes. Specimens were incubated with the primary anti-HSP27 monoclonal antibody (Catalogue No. Clone 2B4; Novocastra Laboratories Ltd, Newcastle, U.K.) and primary anti-HSP27 monoclonal antibody (Catalogue No. Clone 58 F12; Novocastra Laboratories Ltd, Newcastle, U.K.). Specimens were incubated with the primary antibodies for one hour at room temperature. The sections were rinsed three times with PBS at room temperature. The secondary antibody was applied, and immune complexes were identified by Streptavidin peroxidase (Novo Link Polymer detection system). After washing three times with PBS, the immune reactivity was visualized by 3,3'-diaminobenzidine and hydrogen peroxide. Finally, slides were counterstained with hematoxylin and cover slipped with a synthetic mounting media, and then slides were examined by light microscopy. The immunohistochemical staining kit was the Novo Link Polymer detection system (RE7140-K 250T), which is an updated version of Biotin Labeled Streptavidin (LSAB). CD3 ready to use monoclonal antibody (Novocastra Laboratories Ltd., RTU-CD3-PS1), CD20 ready to use monoclonal antibody (Novocastra Laboratories Ltd., RTU-CD20-L26), CD45RO ready to use monoclonal antibody (Novocastra Laboratories Ltd., RTU-UCHL1) and CD68 Lyophilized Concentrated Monoclonal Antibody (Novocastra Laboratories Ltd., NCL-CD68-KP1) were used according to the manufacturer's instruction (Novocastra). No other elements of systemic immune response were measured on patients. For microscopic evaluation within each slide, ten microscopic fields with high density of cells and without tissue defect were selected by the examiner, and evaluated using a light microscope (Leica DMRB). Positive cells were counted under ×100 magnification and this was performed by two independent examiners unaware of study groupings. Micrographs were captured using a Leica Galen III microscope and digital camera (SSSC-DC.58 AP, Sony) ([Figures 1](#f1-epj-09-4961){ref-type="fig"}, [2](#f2-epj-09-4961){ref-type="fig"}).

2.3. Statistical analysis
-------------------------

Differences between groups in terms of each histochemical marker were carried out using One-way ANOVA test. Furthermore, Tukey HSD test was performed as post hoc test. We used SPSS version 15 (SPSS Inc. Chicago, Illinois, USA) for data analysis (Confidence interval: 95%).

3. Results
==========

In total, 82 specimens were available for the analysis, of which 42 blocks belonged to non-smoker groups and 40 to smoker groups. (Half of the blocks were related to the healthy group and the other half were related to the periodontitis group) Only one section for CD68 marker in smoker groups was eliminated because of the low quality of tissue specimen. The number of different infiltration cells with different markers in smoker and non-smoker healthy gingiva (no periodontitis) and periodontitis gingiva was shown in [Table 1](#t1-epj-09-4961){ref-type="table"}. Smoker patients had more CD3, CD68, and CD20 than non-smokers and the differences were significant. However, for CD45RO, there was no significant difference between the two groups. Post-hoc Tukey HSD test was also performed and the results were indicated in [Table 1](#t1-epj-09-4961){ref-type="table"}. The results showed that the proportion of CD45to CD3 in the smoker group was more than the non-smoker group, either in healthy or diseased sites (p=0.019). However, the proportion of macrophage CD68 to CD3 was lower in the smoker group than the non-smoker group, but this difference was not significant. The proportion of CD20 to CD3 in healthy and diseased sites was similar for both groups.

4. Discussion
=============

In our study, gingival biopsies were examined by immuno-histochemical technique which quantified the amount of CD3+, CD20+, CD68+ and CD45RO+ cells in inflammatory infiltrated gingival tissue. Common findings in cigarette smokers is that visual signs of inflammation are diminished among smokers ([@b26-epj-09-4961]). BOP and gingival crevicular fluid (GCF) volumes are reduced ([@b27-epj-09-4961]) and yet, periodontal bone loss is aggravated. In fact, smoking is the strongest environmental risk factor for periodontal attachment loss. The reduction in inflammation together with increased attachment loss sounds somewhat paradoxical. Morozumi et al. showed that smoking cessation increased gingival blood flow and gingival crevicular fluid ([@b28-epj-09-4961]). Ryder et al showed that chronic cigarette smoking reduced gingival blood circulation ([@b29-epj-09-4961]). Johnson et al. showed that smokers have less BOP+ sites, and they found more CD3+, CD8+, CD4+ cells in periodontal tissue in smokers compared with non-smokers. However, the number of B-cells showed no difference between the groups. They concluded that the greater number of T-cells in smokers was one reason for more periodontal destruction. The result of this study was different to our study meanwhile, the mentioned study didn't examine healthy sites in smokers and non-smokers and the sampling and laboratory methods were different. ([@b30-epj-09-4961]) These studies indicated the vasoconstrictor effect of cigarette smoking which may be one reason for the reduction in the number of inflammatory cells. Giannopolou et al. showed that reduction in IL-4 level in smokers prevented the proliferation and function of B-cells ([@b31-epj-09-4961]). Orbach et al. used flow-cytometric analysis and showed that CD4+ and CD8+ cells in smokers were lower than those in non-smokers. Although this study examined limited factors it was in accordance to our study. It should be noted that flowcytometric analysis is more sensitive than immunohistochemical techniques ([@b32-epj-09-4961]). In most of the previous studies, separate test and control groups had been used for comparison of healthy and inflamed tissue ([@b15-epj-09-4961]). However, in our study, biopsies were obtained from two different sites (healthy tissue and diseased tissue) within the same patient suffering from chronic periodontitis. Therefore, it was possible to evaluate the effect of periodontal disease and smoking on gingival tissues while controlling for between subject differences. Our findings showed that there was a greater number of CD3+, CD20+, CD68+ cells among non-smokers compared with smokers in both healthy and periodontitis sites. However, the ratio of CD45RO+ cell/T cell was greater in smokers. These results were also seen at the sites with periodontitis. CD45RO+ cells are markers of memory mononuclear cells. The increase in the ratio of CD45RO+ cells among smokers as compared to nonsmokers may indicate that inflammatory mechanisms due to activity of memory cells might be up-regulated among smokers. It has been reported that cytokines such as IL-1β, IL-6 and TNFα are over expressed in gingival tissues of smokers ([@b15-epj-09-4961], [@b19-epj-09-4961], [@b33-epj-09-4961], [@b34-epj-09-4961]). Our group in a previous report, demonstrated that toll like receptors 2 and 4 (TLR2, TLR4) were up-regulated in the gingival tissue of smokers as compared to non-smokers ([@b25-epj-09-4961]). Memory T-cells are one of the subgroups of T cells which are specific for antigen. These cells may persist in the site of a previous infection for a long time. Upon repeated exposure to their specific antigen, these cells are capable of rapidly expanding into large number of effects or cells which in turn may give rise to increase in the production of cytokines and other aspects of immune response. It is known that antibody production is impaired among smokers as compared to non-smokers ([@b9-epj-09-4961]). The increase in the proportion of memory T-cells observed in our study, may be explained as an effort of the host system to compensate the impaired mechanisms of antibody production. According to our results, inflammatory mononuclear cells are reduced in the gingival tissue of smokers as compared to non-smokers. This held true for both healthy and periodontitis affected periodontium. Moreover, the proportion of memory T-cells is increased among smoker subjects. Periodontitis sites harbored a greater number of mononuclear cells than healthy sites. One of the limitations of our study was that we did not have a group of periodontally healthy patients. In other words, our healthy sites were from patients who had periodontitis in other areas of their dentition. Perhaps if we had such groups of patients, the differences between healthy and periodontitis sites would have been more pronounced. And finally, further studies using additional markers of host immune response are indicated. Power analysis was performed, and for all markers except CDR45RO, the power was over 90%. The required sample size for CDR45RO marker to achieve acceptable power was 637 cases in each group, which was impossible for us to participate this number of cases in our study.

5. Conclusions
==============

Nonsmoker subjects showed significantly greater numbers of CD20+, CD68+, CD3+ cells compared to smoker subjects, both at healthy and periodontitis tissue biopsies. Whereas there was no significant difference in terms of CD45RO. The amount of inflammatory cells including T-cells, macrophages and B-cells in inflamed periodontium was greater than healthy periodontium which proved the role of host defense response to pathogens. Based on our results of this study, the reduction of inflammatory mononuclear cells in both healthy and inflamed periodontium in smokers compared to non-smokers may indicate the immunosuppressive effects of cigarette smoking. This study opens new horizons in the field of immunohistochemistry and its relation to smoking which needs further investigation on different cell types with advanced methods.
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![Left: CD20 marker in diseased periodontium of non-smoker group. IHC technique 100X. Right: CD20 marker in diseased periodontium of smoker group. IHC technique 100X.](EPJ-09-4961-g001){#f1-epj-09-4961}

![Left: CD3 marker in diseased periodontium of non-smoker group. IHC technique 100X. Right: CD3 marker in diseased periodontium of smoker group. IHC technique 100X.](EPJ-09-4961-g002){#f2-epj-09-4961}
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Immunohistochemical evaluation for amount of infiltration cells in the smoker and non-smoker groups in healthy and periodontitis sites.

  Markers         Groups    Subgroups         n                 Mean±SD          p-value
  --------------- --------- ----------------- ----------------- ---------------- ----------
  CD45RO          Smoker    Healthy           20                33.40±28.79      0.120
  Periodontitis   21        47.19±34.20                                          
  Nonsmoker       Healthy   21                31.67±21.98                        
  Periodontitis             54.83±55.29                                          
  CD20            Smoker    Healthy           20                19.70±19.96^a^   0.0002
  Periodontitis   21        21.28±13.84^ac^                                      
  Nonsmoker       Healthy   21                35.05±27.78^ab^                    
  Periodontitis   22        50.78±32.75^b^                                       
  CD68            Smoker    Healthy           19                1.79±1.39^b^     \<0.0001
  Periodontitis   21        2.52±2.71^b^                                         
  Nonsmoker       Healthy   21                10.62±11.20^a^                     
  Periodontitis   22        11.50±8.43^a^                                        
  CD3             Smoker    Healthy           19                46.53±46.15^b^   \<0.0001
  Periodontitis   21        54.76±42.58^bc^                                      
  Nonsmoker       Healthy   21                94.05±50.53^ac^                    
  Periodontitis   24        124.04±80.04^a^                                      

Figures with same alphabetical letter superscription have no significant differences (Tukey HSD test)
